Docteur Arnold MENJUC

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Novel Virtual Reality Simulator for Cleft Palate Surgery Training: An Assessment of Educational Feasibility and Traction Among Plastic Surgery Residents

  The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association · 2026

  📚 3 citations

  Lire l'abstract Crossref ↓

  Objective To evaluate learners’ acceptance of multiuser virtual reality (VR) simulation platform while practicing the Furlow repair technique for cleft palate reconstruction. Design Nonrandomized with pre- and postsurveys. Setting Tertiary care institution's Department of Surgery September 2023 through August 2024. Participants Twenty plastic surgery residents from level PGY1 to PGY6 from a single institution. Interventions Multiuser Meta Quest 2 VR simulation-based workshop with an expert surgeon demonstrating a Furlow cleft palate repair. Feedback included audio and visual. Main outcome measures Learner confidence in using VR as a tool for surgical education, understanding of the Furlow technique, and opinion regarding the incorporation of VR into surgical and medical education. Satisfaction as measured by the Student Evaluation of Educational Quality questionnaire survey with a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). Results 20 residents participated in this study, of which 65% had previously participated in a cleft palate repair and 40% had used VR. After the simulation, trainees’ confidence in using VR as a tool for surgical education, understanding of the Furlow technique, and opinion regarding the incorporation of VR into surgical and medical education significantly increased ( P < .05). Trainees found the simulation stimulating (4.85 ± 0.67), interesting (4.45 ± 0.83), clear (4.60 ± 0.82), an effective teaching tool (4.75 ± 0.44) and would recommend it to others (4.90 ± 0.31). Participants reported that they would feel somewhat comfortable repeating the simulation alone (3.95 ± 1.05). Conclusion Multiuser VR-based simulation workshops can significantly increase learners’ confidence and skills in the Furlow technique and promote positive opinions regarding VR as an educational tool. Learners considered this platform effective and stimulating and would recommend it as an educational tool.

• 2

  A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK -positive Non-small Cell Lung Cancer in the United States

  American journal of clinical oncology · 2026

  📚 2 citations

  Lire l'abstract Crossref ↓

  Objectives: We evaluated the cost-effectiveness of adjuvant alectinib versus adjuvant platinum-based chemotherapy for patients with resectable (stage IB to IIIA) ALK + non-small cell lung cancer using a US societal perspective. Methods: We developed a cohort-level Markov model to compare adjuvant alectinib versus platinum-based chemotherapy using a lifetime time horizon (40 y) with a monthly cycle length and 3% discounting of health state utilities and costs. Patients started in a disease-free health state; downstream health states included treated (first- or second-line) or untreated metastatic or nonmetastatic recurrence, or death. Patient characteristics, adjuvant treatment patterns, and health utilities were based on the ALINA trial. Results: When measured across a lifetime time horizon, adjuvant alectinib was estimated to lead to 3.1 additional quality-adjusted life-years (QALYs) with $429,925 lower total costs per patient, demonstrating a dominant cost-effectiveness ratio compared with adjuvant platinum-based chemotherapy (more effective and less costly). The net monetary benefit in favor of adjuvant alectinib was $895,766 at a willingness-to-pay (WTP) threshold of $150,000/QALY gained. In probabilistic sensitivity analysis, adjuvant alectinib has a 99.6% probability of being more effective and less costly than adjuvant chemotherapy. The incremental cost-effectiveness ratio for adjuvant alectinib remained dominant when all model inputs were varied in the one-way sensitivity analysis. Conclusions: In comparison with platinum-based chemotherapy, adjuvant alectinib offers substantial additional clinical and economic value to society.

• 3

  Camouflaging and autism: Conceptualisation and methodological issues

  Autism : the international journal of research and practice · 2026

  📚 1 citations🔓 Open Access

  Lire l'abstract Crossref ↓

  It has been suggested that there is poor clarity of the ‘camouflaging’ concept in autism research, and potential confounding of its measurement tools, such as the Camouflaging Autistic Traits Questionnaire (CAT-Q). A critical review of 389 studies was conducted to investigate these potential conceptual and methodological issues. The findings question whether the same construct has been investigated across studies, as there is inconsistency in: (a) which terms are used; (b) reference made to established conceptual literature; (c) how terms are used (e.g. interchangeably or distinctly); and (d) how terms are defined. Although the CAT-Q has excellent reliability, there is mixed support for its validity, which is evidenced by its confounding by other constructs (e.g. social anxiety) and its limited autism-specificity. The validity of informant discrepancy measures of camouflaging is also questioned due to insufficient reference to established methodology. Finally, the generalisability of camouflaging to the overall autistic population is unclear due to: (a) overrepresentation of autistic females diagnosed during adulthood; and (b) underrepresentation of autistic people with co-occurring intellectual or language difficulties, and those with greater support needs. These issues are considered both in terms of their clinical relevance and how future research might resolve them. Lay Abstract Many autistic people have reported using ‘camouflaging’ strategies to adapt or cope within the non-autistic social world and avoid being negatively judged by other people. However, many terms have been used synonymously with camouflaging, such as masking, compensation and impression management. Due to this confusion about which terms to use, there is some suggestion that there is poor clarity and understanding of the camouflaging concept, and that this may contribute to inaccuracy of the tools used to measure this behaviour. We review 389 previous studies to examine these concerns. Our findings confirm this lack of clarity by showing that studies are inconsistent in: (a) which terms they used to refer to behavioural strategies that resemble camouflaging; (b) whether they referred to existing literature; (c) whether they used different terms to refer to the same concept or to separate types of behaviour; and (d) how they defined the terms that they used. Our findings also question the accuracy of camouflaging measurement tools, as these tools may also be measuring other behaviours (e.g. social anxiety) that are not only experienced by autistic people. We also find that camouflaging studies have mostly focused on autistic females with no accompanying cognitive or language difficulties, and who have received their diagnosis in adulthood. Although camouflaging may contribute to the underdiagnosis of some autistic females, most autistic people are male and are diagnosed during early childhood, and a large number of autistic people do experience those other difficulties. Because of this, it is not clear whether the findings of previous camouflaging studies can apply to all autistic people. We provide some suggestions for how researchers might resolve some of these issues in their future studies, and we consider what the findings mean for clinicians who work with autistic people.

Publications scientifiques (50) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche